Q2 EPS Forecast for Johnson & Johnson Decreased by Analyst

Johnson & Johnson (NYSE:JNJ) – Analysts at Zacks Research dropped their Q2 2025 EPS estimates for shares of Johnson & Johnson in a report issued on Thursday, December 5th. Zacks Research analyst K. Shah now anticipates that the company will post earnings of $2.68 per share for the quarter, down from their previous estimate of $2.69. The consensus estimate for Johnson & Johnson’s current full-year earnings is $9.93 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q3 2025 earnings at $2.66 EPS.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the previous year, the business earned $2.66 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis.

Other analysts have also recently issued research reports about the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Citigroup raised their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim raised their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Finally, Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.67.

Johnson & Johnson Trading Down 0.1 %

Shares of Johnson & Johnson stock opened at $149.31 on Monday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $158.09 and its 200-day moving average is $156.40. The stock has a market cap of $359.48 billion, a P/E ratio of 21.61, a P/E/G ratio of 2.67 and a beta of 0.51.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Vinva Investment Management Ltd boosted its position in shares of Johnson & Johnson by 6.8% during the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock worth $17,988,000 after acquiring an additional 7,110 shares in the last quarter. Financial Counselors Inc. boosted its holdings in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after purchasing an additional 9,309 shares in the last quarter. Meridian Financial Partners LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at $1,626,000. Meridian Investment Counsel Inc. raised its holdings in shares of Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after buying an additional 3,710 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after buying an additional 102,502 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.